ILF2 and gastric cancer: The median and mean survival times of GC patients with high ILF2 expression, respectively, were 38 months and 36.519 ± 2.985 months, which were shorter than those with low expression groups (median 60 months, mean 53.043 ± 2.916 months) (p < 0.001, log-rank test, Figure 5(a)).